NEUROCRINE BIOSCIENCES INC Increase (Decrease) in Other Operating Assets and Liabilities, Net
NEUROCRINE BIOSCIENCES INC (NBIX) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of -$47.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was -$78.80M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was $31.40M.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was $27.80M, a 2.46% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was $42.10M, a 123.94% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was $44.40M, a 17.78% decline from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was $54.00M, a 89.47% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was $28.50M, a 65.70% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was $17.20M, a 86.96% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$78.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$47.40M 10-Q · filed 2026-07-31 | -$19.60M derived: sum of 3 quarters · filed 2026-07-31 | $22.50M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2026-03-31 | $31.40M 10-Q · filed 2026-05-05 | $59.20M derived: sum of 2 quarters · filed 2026-05-05 | $101.30M derived: sum of 3 quarters · filed 2026-05-05 | $78.30M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2025-12-31 | $27.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $69.90M derived: sum of 2 quarters · filed 2026-02-11 | $46.90M derived: sum of 3 quarters · filed 2026-07-31 | $44.40M 10-K · filed 2026-02-11 | |||
| 2025-09-30 | $42.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $19.10M derived: sum of 2 quarters · filed 2026-07-31 | $16.60M 10-Q · filed 2025-10-28 | $45.10M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2025-06-30 | -$23.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | -$25.50M 10-Q · filed 2026-07-31 | $3.00M derived: sum of 3 quarters · filed 2026-07-31 | $21.80M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2025-03-31 | -$2.50M 10-Q · filed 2026-05-05 | $26.00M derived: sum of 2 quarters · filed 2026-05-05 | $44.80M derived: sum of 3 quarters · filed 2026-05-05 | $48.70M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $28.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $47.30M derived: sum of 2 quarters · filed 2026-02-11 | $51.20M derived: sum of 3 quarters · filed 2026-02-11 | $54.00M 10-K · filed 2026-02-11 | -$10.70M 10-K · filed 2025-02-10 | ||
| 2024-09-30 | $18.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $22.70M derived: sum of 2 quarters · filed 2025-10-28 | $25.50M 10-Q · filed 2025-10-28 | $50.20M derived: sum of 4 quarters · filed 2026-02-11 | |||
| 2024-06-30 | $3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $6.70M 10-Q · filed 2025-07-30 | $31.40M derived: sum of 3 quarters · filed 2026-02-11 | $82.30M derived: sum of 4 quarters · filed 2026-02-11 | |||
| 2024-03-31 | $2.80M 10-Q · filed 2025-05-05 | $27.50M derived: sum of 2 quarters · filed 2026-02-11 | $78.40M derived: sum of 3 quarters · filed 2026-02-11 | $7.00M derived: sum of 4 quarters · filed 2026-02-11 | |||
| 2023-12-31 | $24.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $75.60M derived: sum of 2 quarters · filed 2026-02-11 | $4.20M derived: sum of 3 quarters · filed 2026-02-11 | $28.50M 10-K · filed 2026-02-11 | -$47.80M 10-K · filed 2024-02-09 | ||
| 2023-09-30 | $50.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$20.50M derived: sum of 2 quarters · filed 2024-10-30 | $3.80M 10-Q · filed 2024-10-30 | $300.00K derived: sum of 4 quarters · filed 2025-02-10 | |||
| 2023-06-30 | -$71.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$47.10M 10-Q · filed 2024-08-01 | -$50.60M derived: sum of 3 quarters · filed 2025-02-10 | -$32.10M derived: sum of 4 quarters · filed 2025-02-10 | |||
| 2023-03-31 | $24.30M 10-Q · filed 2024-05-01 | $20.80M derived: sum of 2 quarters · filed 2025-02-10 | $39.30M derived: sum of 3 quarters · filed 2025-02-10 | $30.80M derived: sum of 4 quarters · filed 2025-02-10 | |||
| 2022-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $15.00M derived: sum of 2 quarters · filed 2025-02-10 | $6.50M derived: sum of 3 quarters · filed 2025-02-10 | $17.20M 10-K · filed 2025-02-10 | |||
| 2022-09-30 | $18.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $10.00M derived: sum of 2 quarters · filed 2023-10-31 | $20.70M 10-Q · filed 2023-10-31 | $8.20M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-06-30 | -$8.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $2.20M 10-Q · filed 2023-08-01 | -$10.30M derived: sum of 3 quarters · filed 2024-02-09 | $16.90M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-03-31 | $10.70M 10-Q · filed 2023-05-03 | -$1.80M derived: sum of 2 quarters · filed 2024-02-09 | $25.40M derived: sum of 3 quarters · filed 2024-02-09 | $21.60M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2021-12-31 | -$12.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $14.70M derived: sum of 2 quarters · filed 2024-02-09 | $10.90M derived: sum of 3 quarters · filed 2024-02-09 | $9.20M 10-K · filed 2024-02-09 | |||
| 2021-09-30 | $27.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $23.40M derived: sum of 2 quarters · filed 2022-11-01 | $21.70M 10-Q · filed 2022-11-01 | ||||
| 2021-06-30 | -$3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$5.50M 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | -$1.70M 10-Q · filed 2022-05-04 | ||||||
| 2020-09-30 | $31.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $28.50M derived: sum of 2 quarters · filed 2021-11-01 | $35.30M 10-Q · filed 2021-11-01 | $29.70M 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | -$2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $4.10M 10-Q · filed 2021-08-03 | $1.40M 10-Q · filed 2020-08-03 | ||||
| 2020-03-31 | $6.80M 10-Q · filed 2021-05-05 | ||||||
| 2019-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$12.40M 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | -$11.30M 10-Q · filed 2020-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |